Table 1.
Demographic and clinical information for individuals with FRDA and healthy controls
| FRDA (n = 31) | Controls (n = 36) | Statistic | p Value | |
|---|---|---|---|---|
| Demographic | ||||
| Age (years) | 36.6 ± 13.0 (Range 18–63) | 36.5 ± 12.5 (Range 18–62) | U = 536 | .782 |
| Gender (M, F) | (17, 14) | (20, 16) | χ2(1) = .003 | .953 |
| Clinical data | ||||
| BDI‐II score | 8.2 ± 8.4 (Range 0–39) | 5.1 ± 5.8 (Range 0–24) | U = 425 | .093 |
| Age at disease onset (years) | 19.6 ± 8.8 (Range 6–40) | – | – | – |
| Disease duration (years) | 16.9 ± 9.5 (Range 5–48) | – | – | – |
| FARS score | 80.9 ± 28.4 (Range 19–126) | – | – | – |
| GAA1 repeat length | 546 ± 225 (Range 126–1,077) | – | – | – |
| GAA2 repeat length | 864 ± 253 (Range 215–1,293) | – | – | – |
Note: Mean ± SD. GAA = number of GAA repeats in intron 1 of the FXN gene on the smaller (GAA1) and larger (GAA2) alleles.
Abbreviations: BDI‐II, Beck Depression Inventory II; FARS, Friedreich Ataxia Rating Scale; U, Mann–Whitney U‐test; χ 2, chi‐square test.